✦ LIBER ✦

Progress in the development of an adenovirus 26 vector platform for HIV vaccines

✍ Scribed by Esparza, José

Book ID: 120361959
Publisher: Expert Reviews
Year: 2013
Tongue: English
Weight: 822 KB
Volume: 12
Category: Article
ISSN: 1476-0584
DOI: 10.1586/erv.13.26

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P17-27. Development of recombinant adeno

P17-27. Development of recombinant adenovirus 28 vectors for HIV vaccines

✍ S Ko, L Wang, C Cheng, W Kong, J Gall, R King, GJ Nabel 📂 Article 📅 2009 🏛 BioMed Central 🌐 English ⚖ 66 KB

Progress in development and testing of n

Progress in development and testing of novel recombinant vaccine platforms for HIV

✍ Weiner, David B. 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 55 KB

Progress in the Development of an HIV-1

Progress in the Development of an HIV-1 Vaccine

✍ Letvin, N. L. 📂 Article 📅 1998 🏛 American Association for the Advancement of Scienc 🌐 English ⚖ 281 KB

OA05-06 LB. First-in-human Phase 1 safet

OA05-06 LB. First-in-human Phase 1 safety and immunigenicity of an adenovirus serotype 26 HIV-1 vaccine vector

✍ LR Baden, R Dolin, KL O'Brien, P Abbink, A La Porte, MS Seaman, E Choi… 📂 Article 📅 2009 🏛 BioMed Central 🌐 English ⚖ 63 KB

Progress towards development of an HIV v

Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference

✍ Anna Laura Ross; Andreas Bråve; Gabriella Scarlatti; Amapola Manrique; Luigi Buo 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 713 KB

The prevalence of antibodies to adenovir

The prevalence of antibodies to adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines

✍ Rajendra Pilankatta; Tanu Chawla; Navin Khanna; Sathyamangalam Swaminathan 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB 👁 1 views

## Abstract In vivo gene delivery using human adenovirus serotype 5 (AdV5) vectors is being explored for vaccination purposes. The presence of anti‐AdV5 antibodies in human serum arising from natural exposure to AdV5 can interfere potentially with and compromise the efficacy of rAdV5‐based vaccine